… In total, we identified 3257 rivaroxaban and 5046 warfarin users eligible for study inclusion.
Of those patients receiving rivaroxaban, 30.4% we prescribed the 15 mg once daily dose. …

… in non-valvular atrial fibrillation (NVAF) patients and a potent risk factor for … warfarin. We
assessed the real-world effectiveness and safety of rivaroxaban and warfarin in NVAF patients …

… In this study, we show that among newly anticoagulated NVAF patients in the real-world US
setting, initiation with rivaroxaban or warfarin was associated with a significantly greater risk …

… In this study, patients receiving rivaroxaban for NVAF had 37% lower hazard of non-… those
receiving warfarin. In the subset of patients who did not switch OAC, rivaroxaban patients were …

… We selected NVAF patients initiating oral anticoagulant use in 2010–2014 enrolled in
MarketScan databases. Rivaroxaban users were matched with warfarin and dabigatran users by …

… the case for rivaroxaban use as an alternative to warfarin in the elderly, including … NVAF
patients ≥80 years of age found consistent effectiveness and safety results for rivaroxaban …

… present study in patients with NVAF and comorbid T2D, treated in routine practice, rivaroxaban
was found to be associated with lower risk of both MACE and MALE versus warfarin, with …

… In contrast, rivaroxaban, an oral factor Xa inhibitor (oFXaI) … the impact of rivaroxaban and
warfarin on the development of … dialysis in diabetic patients NVAF treated in routine practice. …

… (NVAF). There are limited data on the comparative risks of major bleeding among newly
anticoagulated NVAF patients who initiate warfarin, apixaban, dabigatran, or rivaroxaban, when …

… We included 3319 rivaroxaban and 3319 warfarin patients with a non-sex-related CHA 2
DS 2 -VASc score = 1 (Table 1). All baseline covariates had an absolute standardized …